Blog

COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023

Jul 31 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023. The management team will host a conference call at 8:00 am…

Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

Jul 28 • 20 min read

Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL / NASDAQ: IXHL), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2023. Incannex is undertaking a multitude of U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine…

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

Jul 28 • 2 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF / CSE: RVV / FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a…

Mind Cure Announces LNG Energy Group Credit Agreement in the Amount of U.S. $70 Million to Acquire Lewis Energy Colombia, Inc.

Jul 28 • 2 min read

Mind Cure Health Inc. (CSE: MCUR / OTC: MCURF) is pleased to announce that a wholly-owned subsidiary of LNG Holdings Inc. (formerly known as LNG Energy Group Inc.) (“LNG Energy“) has entered into a definitive credit agreement (the “Credit Agreement“) with Macquarie Group (the “Lender“) in the aggregate principal amount of U.S.$70 million in order to complete…

Optimi Health Announces Receipt of Purported Termination Notice

Jul 28 • 2 min read

Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further details of the Supply Agreement, see the Company’s press release dated May 4, 2023, a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538